Zimmer Biomet stock price forecast: sideways trend persists as ZBH faces sustained downtrend

Traders Union
All News
Companies
Zimmer Biomet slides 0.65% today

Highlights

ZBH remains under sustained selling pressure, trading below key short-, medium-, and long-term moving averages.
Technical momentum indicators show persistent weakness, with the probability of a price increase below 20% and a moderate downtrend prevailing.
ZBH is likely to fluctuate between $87.00 and $90.50 next week, with $87.00 as critical support and resistance near $93.66 and $95.11.

ZBH is trading at $88.57, remaining below the MA-20 ($91.87), MA-50 ($91.85), and MA-200 ($95.11), which signals persistent short-, medium-, and long-term seller pressure. The Ichimoku Kijun sits at $93.66, standing as immediate resistance, while near-term support is offered by the MA-5 cluster ($87.90–$88.48), with key support at MA-100 ($91.86–$93.10) and key resistance at the MA-200 ($95.11).

Momentum on D1 is weak, with the MACD in negative territory and signaling a sell, while the ADX at 21.26 confirms a moderate downtrend. RSI sits at 40.52, CCI at –81.91, and Stoch RSI remains neutral, showing the market leans toward but is not yet oversold. BBP on D1 is oversold at –0.76, indicating sellers maintain control intraday. Over the past week, ZBH has risen $0.70 (0.80%) from the previous weekly close of $87.87, with the current price positioned in the upper part of the weekly range. Weekly volatility stands at 4.4%. The recovery from the weekly low suggests some stabilization despite overall bearish momentum.

For the coming week, ZBH is expected to fluctuate between $87.00 and $90.50, which keeps the price above the 52-week low of $84.59 but well below the 52-week high of $114.44. The probability of a price increase is very low (less than 20%), with the likelihood of further decline notably higher, as all weekly trend indicators (MA-50 W1, RSI W1, ADX W1, MACD W1) signal continued weakness. The baseline scenario envisions ZBH holding within a sideways corridor near current levels. A bullish scenario requires a breakout above $93.66 (immediate resistance), potentially testing the MA-200 region near $95.11. In a bearish scenario, loss of support at $87.00 could lead to a rapid test of the yearly low near $85. Sustained weakness and lack of upside momentum define the short-term outlook.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Previously it was reported that Zimmer Biomet received national recognition for its innovation efforts in the medical device space. Investors should now monitor for any signs of operational momentum translating into sustained financial performance, with particular attention to upcoming quarterly results as a potential catalyst.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.